Humanized Anti-CD40 Formulations for Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating humanized anti-CD40 antibodies into suitable pharmaceutical compositions for effective in vivo administration to suppress the immune system in organ transplantation and treat autoimmune disorders is challenging due to stability and aggregation issues.
Innovation Solution
A pharmaceutical composition comprising humanized anti-CD40 antibodies with specific amino acid sequence identities, combined with excipients like polysorbate 20, acetate, and polar compounds such as sugars or amino acids, enhances stability and reduces aggregation, allowing high concentration formulation and improved viscosity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If humanized anti-CD40 antibodies are formulated at high concentrations for effective immune suppression, then therapeutic efficacy is improved, but aggregation and instability increase
Solution Approach 1:
The patent introduces multiple excipients as intermediary substances to mediate between the high-concentration antibody and the formulation system. Specifically, polysorbate 20 acts as a surfactant intermediary to prevent aggregation, while acetate and polar excipients (sugars, polyols, or amino acids) serve as stabilizing intermediaries that maintain antibody solubility and structural integrity at high concentrations without compromising therapeutic efficacy
2Stability of the object's composition
If excipients are added to reduce aggregation and improve stability, then antibody stability is improved, but formulation complexity increases
Solution Approach 1:
The patent optimizes specific concentration parameters of each excipient to achieve stability with minimal formulation complexity. The defined ranges (polysorbate 20: 0.003-0.5%, acetate: 10-100 mM, polar excipients: 5-150 mM) represent parameter optimizations that provide sufficient stabilizing effect while avoiding excessive complexity. This systematic parameter control allows the formulation to achieve high stability without requiring numerous or high-concentration excipients
3Stability of the object's composition
If polysorbate 20 is included in the formulation, then aggregation is reduced and stability is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent defines a relatively broad acceptable range for polysorbate 20 concentration (0.003-0.5%, with preferred sub-range of 0.01-0.1%), which provides manufacturing flexibility while ensuring adequate aggregation prevention. This parameter range optimization reduces the stringency of manufacturing precision requirements compared to formulations requiring tighter control, while still achieving the desired stability and aggregation prevention effects
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions of anti-CD40 antibodies, such as humanized anti-CD40 antibodies. The pharmaceutical compositions may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies block the ability of CD40 to bind CD154 without activating the cell expressing CD40 (e.g., a B cell).